|1.||Beck-Sickinger, Annette G: 2 articles (04/2015 - 02/2007)|
|2.||Subhedar, Nishikant K: 2 articles (08/2009 - 05/2009)|
|3.||Dandekar, Manoj P: 2 articles (08/2009 - 05/2009)|
|4.||Kokare, Dadasaheb M: 2 articles (08/2009 - 05/2009)|
|5.||Fukuoka, T: 1 article (09/2015)|
|6.||Noguchi, K: 1 article (09/2015)|
|7.||Simonin, Frederic: 1 article (08/2015)|
|8.||De Prins, An: 1 article (08/2015)|
|9.||Balasubramaniam, Ambikaipakan: 1 article (08/2015)|
|10.||Bertin, Isabelle: 1 article (08/2015)|
04/06/2015 - "In vitro autoradiography with Y1R-positive MCF-7 tumor tissue slices indicated high specific binding of the (18)F-labeled glycopeptide, when binding was reduced by 95% ([Pra(4),F(7),P(34)]NPY) and by 86% (BIBP3226 Y1R antagonist) in competition studies. "
04/26/2001 - "This cytotoxicity is Y(1) receptor-mediated as shown in blocking studies with BIBP 3226, because tumor cells that do not express NPY receptors were sensitive to free daunorubicin, but not to the peptide-drug conjugate. "
10/01/2002 - "Local BIBP3226 perfusion essentially abolished the ECS-induced seizure but had no effect on the basal NPY-LI outflow or on the ECS-induced rise in extracellular NPY levels. "
10/01/2002 - "We also studied the effect of locally administered BIBP3226, a selective NPY Y1 receptor antagonist with reported anticonvulsant properties, on the duration of the ECS-induced seizure and NPY release in freely moving animals. "
02/01/1998 - "Intrahippocampal administration of 10 microg BIBP3226 (N2- (diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]D-arginamide), a non-peptide selective antagonist at the NPY Y1 receptors, increased threefold on average (P < 0.01) the time to onset of seizures and reduced the number of seizures and the total time in seizures three- and fourfold, respectively (P < 0.01). "
04/01/2000 - "Similarly, kainate seizures were reduced by N[-2-(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl-D-arginamide++ +] (BIBP 3226), a NPY Y(1) receptor antagonist. "
01/01/2000 - "Compared with naive controls, [125I][Leu(31), Pro(34)]PYY/BIBP3226-insensitive (Y(5)) binding sites in the hippocampus (strata oriens and radiatum of CA3 and CA1) and in the neocortex (superficial layers) were unchanged in sham-stimulated rats, but reduced by approximately 50% in kindled rats (seven days after the last stimulus evokes seizure), and further reduced (to approximately -90%) 1h after a kindled seizure. "
|3.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
01/01/2003 - "Intracerebroventricular injection of a neuropeptide Y-Y1 receptor agonist increases while BIBP3226, a Y1 antagonist, reduces the infarct volume following transient middle cerebral artery occlusion in rats."
04/15/2002 - "In a rat endovascular middle cerebral artery occlusion (MCAO) stroke model, we previously showed that intracerebroventricular (ICV) injection of neuropeptide Y (NPY) or an Y1 receptor agonist, [Leu(31),Pro(34)]-NPY, increased the infarct volume, that an Y1 receptor antagonist, BIBP3226, reduced the infarct volume, and that an Y2 receptor agonist, NPY3-36, had no effect. "
01/01/2003 - "In this study, we investigated the effects of an i.c.v. injection of a neuropeptide Y-Y2 receptor agonist, neuropeptide Y 3-36, a Y1 receptor agonist, [Leu(31),Pro(34)]-neuropeptide Y, or a Y1 receptor antagonist, BIBP3226, on infarct volume and hemodynamic parameters following middle cerebral artery occlusion. "
09/24/2015 - "Bolus intracisternal injection of BIBP3226, a Y1 receptor antagonist, dose-dependently reversed mechanical allodynia. "
08/01/2009 - "In acute study, intracerebroventricular (icv) administration of morphine, NPY or NPY Y1/Y5 receptors agonist [Leu(31),Pro(34)]-NPY produced antinociception, whereas selective NPY Y1 receptors antagonist BIBP3226 caused hyperalgesia. "
|5.||Hypertension (High Blood Pressure)
01/01/1997 - "To study the effects of the selective neuropeptide Y (NPY) Y1 receptor antagonist BIBP 3226 in spontaneously hypertensive rats (SHR) in order to elucidate whether NPY function may be altered in the SHR and whether the NPY Y1 receptor plays a specific role in the maintenance of high blood pressure in this genetic form of hypertension. "
|2.||Leu(31)-Pro(34)- neuropeptide Y (NY-LP)
|4.||Morphine (MS Contin)
|7.||neuropeptide Y (3-36)
|8.||neuropeptide FF receptor
|10.||Kainic Acid (Kainate)